BOYDSense SAS, subsidiary of Alpha MOS (Euronext Paris, ISIN: FR0013421286 ALNEO), announces that they have been recognized and awarded in the category “diabetes devices” from the DCB Innovation Challenge 2022.
Held every year, the DCB Open Innovation Challenge aims at fostering new initiatives and innovative projects in the domain of diabetes management.
BOYDSense breath-based glucose monitoring device competed alongside 70 projects from 22 countries in the 2022 edition.
BOYDSense project successfully passed the first selection step and was among the 3 finalists presenting their work during the Start-Up Night and Award Ceremony end of November.
At the end of the Challenge, the Expert Jury, composed of leading scientists, leading Health Care Professionals and Patients living with Diabetes, decided to award BOYDSense with a financial reward.
Ben Delhey, CEO of BOYDSense, comments: “We feel honored and proud to be awarded from the DCB Innovation Challenge 2022 leading expert jury for our work we do to develop a non-invasive health monitoring platform to monitor chronic diseases, starting with Diabetes.
This distinction will also open us new networking and collaboration perspectives and leverage the development of our breath-based glucose monitoring device.”